Compounding R.Ph.s demand transparency from FDA over bio-identical hormones

March 5, 2008

The International Academy of Compounding Pharmacists wants to find out when the Food & Drug Administration became interested in cracking down on the use of estriol for bio-identical hormone replacement therapy.

Still smarting from the Food & Drug Administration's International Academy of Compounding Pharmacists has filed three Freedom of Information Act requests with the agency, seeking documents related to this subject. IACP wants to make sure that FDA's interest in sanctioning estriol is not pursuant to a citizen's petition filed by Wyeth, a leading maker of HRT, but rather predates the brand drugmaker's 2005 petition. IACP contends that by law, federal agencies are prohibited from taking enforcement actions following a citizen's petition.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.